Investors

About

Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.

The company’s lead development program, vidofludimus calcium (IMU-838), currently in phase 3 clinical trials for the treatment of multiple sclerosis and which has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis, selectively inhibits activated immune cells and shows combined anti-inflammatory, anti-viral and neuroprotective effects. IMU-856 is targeted to restore intestinal barrier function and regenerate bowel epithelium, which would be applicable in numerous gastrointestinal diseases, such as celiac disease, where it is currently in preparations for a phase 2 clinical trial.

Stock Quote
NASDAQIMUX
Fast Facts
  •  Company Founded in 2016
  •  Experts in Selective Oral Drugs in Immunology
  •  Differentiated Development Programs
  •  Headquartered in New York City
  •  NASDAQ: IMUX
Latest News
May 30, 2023

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today...

May 17, 2023

– Preclinical Data Published in the Peer-Reviewed Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator – – Nurr1 Activation Suggested to Prevent...

May 11, 2023

– Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal Diseases by Promoting Regeneration...

View All

Contact Us

Immunic Therapeutics
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

Rx Communications
Paula Schwartz
Managing Director
+1 917 322 2216
immunic@rxir.com

Subscribe
To receive all investor alerts please subscribe here
* Required Fields